Table 5.
The impact of investigated polymorphisms on chronic and neuropathic pain (N = 101)
| SNP | Genotype | Chronic N (%) pain | OR (95% CI) | P | OR (95% CI)adj | Padj |
|---|---|---|---|---|---|---|
| OPRM1 rs1799971 | AA | 15 (20.3) | Ref. | Ref. | ||
| AG+GG | 6 (22.2) | 1.12 (0.39–3.28) | 0.831 | 1.2 (0.4–3.57) | 0.739 | |
| OPRMrs677830 1 | CC | 14 (27.5) | Ref. | Ref. | ||
| CT+TT | 7 (14) | 0.43 (0.16–1.18) | 0.101 | 0.44 (0.16–1.21) | 0.112 | |
| MIR23B rs1011784 | CC | 9 (15.3) | Ref. | Ref. | ||
| CG | 10 (32.3) | 2.65 (0.94–7.45) | 0.065 | 2.85 (0.99–8.19) | 0.052 | |
| GG | 2 (20) | 1.39 (0.25–7.64) | 0.706 | 1.68 (0.29–9.83) | 0.563 | |
| MIR107 rs2296616 | CG+GG GG | 12 (29.3) 0 (0) | 2.3 (0.86–6.11) Ref. | 0.095 | 2.58 (0.94–7.1) Ref. | 0.067 |
| GA | 9 (18.4) | / | 0.099* | |||
| AA | 12 (35.3) | / | 0.004* | |||
| GA+AA | 21 (25.3) | / | 0.021* | |||
| SNP | Genotype | Neuropathic pain N (%) | OR (95% CI) | P | OR (95% CI)adj | Padj |
| OPRM1 rs1799971 | AA | 19 (25.7) | Ref. | Ref. | ||
| AG+GG | 6 (22.2) | 0.83 (0.29–2.36) | 0.722 | 0.94 (0.32–2.75) | 0.915 | |
| OPRMrs677830 1 | CC | 17 (33.3) | Ref. | Ref. | ||
| CT+TT | 8 (16) | 0.38 (0.15–0.99) | 0.047 | 0.4 (0.15–1.04) | 0.060 | |
| MIR23B rs1011784 | CC | 11 (18.6) | Ref. | Ref. | ||
| CG | 12 (38.7) | 2.76 (1.04–7.31) | 0.042 | 3.25 (1.17–9.02) | 0.023 | |
| GG | 2 (20) | 1.09 (0.2–5.87) | 0.919 | 1.59 (0.27–9.24) | 0.607 | |
| CG+GG | 14 (34.1) | 2.26 (0.9–5.68) | 0.082 | 2.85 (1.07–7.59) | 0.036 | |
| MIR107 rs2296616 | GG | 3 (16.7) | Ref. | Ref. | ||
| GA | 11 (22.4) | 1.45 (0.35–5.93) | 0.607 | 1.37 (0.33–5.69) | 0.666 | |
| AA | 11 (32.4) | 2.39 (0.57–10.02) | 0.233 | 2.34 (0.55–9.97) | 0.249 | |
| GA+AA | 22 (26.5) | 1.8 (0.48–6.83) | 0.386 | 1.73 (0.45–6.65) | 0.424 |
adj = adjustment for tramadol dose, N = sample size, OR = odds ratio, SNP = single nucleotide polymorphism, 95% CI = 95% confidence interval; *calculated using Fisher’s exact test